Journal of Internal Medicine Concepts & Practice >

2024 , Vol. 19 >Issue 06: 357 - 362

DOI: https://doi.org/10.16138/j.1673-6087.2024.06.01

Guideline and consensus

Expert consensus on multidisciplinary diagnosis and treatment of primary Sjögren syndrome (2024 edition)

  • CHENG Fang ,
  • ZHAO Futao ,
  • SHEN Xuemin ,
  • LI Jin ,
  • CHEN Xiangjun ,
  • WANG Guifang ,
  • LI Huilin ,
  • XUE Luan ,
  • QI Junyuan
Expand
  • 1a. Department of Rheumatology and Immunology; b. Department of Oral Medicine; c. Department of Ophthalmology, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, China
    2a. Department of Neurology; b. Department of Respiratory Medicine, Huashan Hospital, Fudan University, Shanghai 200040, China
    3. Department of Nephrology, Gongli Hospital of Shanghai Pudong New Area, Naval Military Medical University, Shanghai 200135, China
    4. Department of Rheumatology and Immunology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 200437, China
    5. Department of Hematology, Blood Diseases Hospital, Chinese Academy of Medical Science, Tianjin 300020, China

Received date: 2024-11-27

  Online published: 2025-03-11

Fold

Abstract

Primary Sjögren syndrome (PSS) is an autoimmune disease characterized by lymphocytic infiltration of exocrine glands and other organs. PSS shows strong clinical heterogeneity, presents different degrees of topical and systemic damage, and multidisciplinary collaboration are required to develop PSS treatment strategies. However, our country currently has not unified diagnosis and treatment consensus for PSS. Based on domestic and foreign diagnosis and treatment experience, consensus and guideline, experts from multiple related disciplines achieved consensus using the nominal group technique, providing guidance and reference for standardized diagnosis and treatment of PSS.

Key words： Sjögren syndrome; Multiple-disciplinary team; Diagnosis; Treatment

Cite this article

CHENG Fang , ZHAO Futao , SHEN Xuemin , LI Jin , CHEN Xiangjun , WANG Guifang , LI Huilin , XUE Luan , QI Junyuan . Expert consensus on multidisciplinary diagnosis and treatment of primary Sjögren syndrome (2024 edition)[J]. Journal of Internal Medicine Concepts & Practice, 2024 , 19(06) : 357 -362 . DOI: 10.16138/j.1673-6087.2024.06.01

References

[1] Shiboski CH, Shiboski SC, Seror R, et al. 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjogren’s syndrome[J]. Ann Rheum Dis, 2017, 76(1): 9-16.
[2] Seror R, Bowman SJ, Brito-Zeron P, et al. EULAR Sj?gren’s syndrome disease activity index (ESSDAI)[J]. RMD Open, 2015, 1(1): e000022.
[3] 张文, 厉小梅, 徐东, 等. 原发性干燥综合征诊疗规范[J]. 中华内科杂志, 2020, 59(4): 269-276.
[4] 张文, 陈竹, 厉小梅, 等. 原发性干燥综合征诊疗规范[J]. 中华内科杂志, 2023, 62(9): 1059-1067.
[5] Trevisani VFM, Pasoto SG, Fernandes MLMS, et al. Recommendations from the Brazilian society of rheumatology for the diagnosis of Sjogren’s syndrome (Part I)[J]. Adv Rheumatol, 2019, 59(1): 58.
[6] Jousse-Joulin S, D’Agostino MA, Nicolas C, et al. Video clip assessment of a salivary gland ultrasound scoring system in Sj?gren’s syndrome using consensual definitions: an OMERACT ultrasound working group reliability exercise[J]. Ann Rheum Dis, 2019, 78(7): 967-973.
[7] Ramos-Casals M, Brito-Zerón P, Bombardieri S, et al. EULAR recommendations for the management of Sjogren’s syndrome with topical and systemic therapies[J]. Ann Rheum Dis, 2020, 79(1): 3-18.
[8] 亚洲干眼协会中国分会, 海峡两岸医药卫生交流协会眼科学专业委员会眼表与泪液病学组, 中国医师协会眼科医师分会眼表与干眼学组, 等. 中国干眼专家共识:免疫性疾病相关性干眼(2021年)[J]. 中华眼科杂志, 2021, 57(12): 898-907.
[9] Trevisani VFM, Pugliesi A, Pasoto SG, et al. Recommendations for evaluation and diagnosis of extra-glandular manifestations of primary sjogren syndrome: results of an epidemiologic systematic review/meta-analysis and a consensus guideline from the Brazilian Society of Rheumatology (articular, pulmonary and renal)[J]. Adv Rheumatol, 2022, 62(1):18.
[10] Yueting L, Lin Q, Jian X, et al. Long-term survival analysis of patients with primary Sj?gren’s syndrome in China[J]. Int J Rheum Dis, 2024, 27(9): e15284.
[11] Lee AS, Scofield RH, Hammitt KM, et al. Consensus guidelines for evaluation and management of pulmonary disease in Sjogren’s[J]. Chest, 2021, 159(2): 683-698.
[12] Trevisani VFM, Pinheiro AC, de Magalh?es Souza Fialho SC, et al. Recommendations for evaluation and diagnosis of extra-glandular manifestations of primary Sjogren syndrome: results of an epidemiologic systematic review/meta-analysis and a consensus guideline from the Brazilian society of rheumatology (hepatic, gastrointestinal and pancreatic)[J]. Adv Rheumatol, 2022, 62(1): 35.
[13] Xu D, Fang J, Zhang S, et al. Efficacy and safety of telitacicept in primary Sj?gren’s syndrome: a randomized, double-blind, placebo-controlled, phase 2 trial[J]. Rheumatology (Oxford), 2024, 63(3): 698-705.
[14] Alunno A, Carubbi F, Bartoloni E, et al. The kaleidoscope of neurological manifestations in primary Sj?gren’s syndrome[J]. Clin Exp Rheumatol, 2019, 37 Suppl 118(3):192-198.
[15] Pugliesi A, Egypto DCSD, Duffles G, et al. Recommendations on cutaneous and hematological manifestations of Sj?gren’s disease by the Brazilian Society of Rheumatology[J]. Adv Rheumatol, 2024, 64(1): 51.
[16] 中华中医药学会风湿病分会. 干燥综合征病证结合诊疗指南[J]. 中医杂志, 2024, 65(4): 434-444.
[17] Baldini C, Fulvio G, La Rocca G, et al. Update on the pathophysiology and treatment of primary Sj?gren syndrome[J]. Nat Rev Rheumatol, 2024, 20(8): 473-491.
Options
Outlines

/

〈 〉